Miacalcic ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
225Congenital nephrogenic diabetes insipidus1

225. Congenital nephrogenic diabetes insipidus


Clinical trials : 15 Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-003360-56-DK
(EUCTR)
28/08/200907/07/2009Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDYFarmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY Kongenit nefrogen diabetes insipidus
MedDRA version: 14.1;Level: PT;Classification code 10068304;Term: Congenital nephrogenic diabetes insipidus;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Confortid
INN or Proposed INN: INDOMETACIN
Trade Name: Losec
INN or Proposed INN: OMEPRAZOLE MAGNESIUM
Trade Name: Viagra
Other descriptive name: SILDENAFIL CITRATE
Trade Name: Miacalcic
Other descriptive name: CALCITONIN (SALMON)
Trade Name: Spirix
Other descriptive name: SPIRONOLACTONE
Trade Name: Esidrix
Product Name: Esidrix
INN or Proposed INN: HYDROCHLOROTHIAZIDE
Dept. of Pediatrics, The Childrens Hospital, DenverNULLNot RecruitingFemale: no
Male: yes
40Denmark